References
Uncategorized References
- Postow MA, Sidlow R, Hellmann MD. Immune-Related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168.
- Kwok G, Yau TC, Chiu JW, et al. Pembrolizumab (keytruda). Hum Vaccin Immunother. 2016;12(11):2777–2789.
- Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559–574.
- Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306.
- Zhai Y, Ye X, Hu F, et al. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US food and drug administration adverse events reporting system. J Immunother Cancer. 2019;7(1):286.
- Safa H, Johnson DH, Trinh VA, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019;7(1):319.
- Kesner VG, Oh SJ, Dimachkie MM, et al. Lambert-Eaton myasthenic syndrome. Neurol Clin. 2018;36(2):379–394.
- Wirtz PW, Smallegange TM, Wintzen AR, et al. Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg. 2002;104(4):359–363.
- Agrawal K, Agrawal N. Lambert-Eaton myasthenic syndrome secondary to nivolumab and ipilimumab in a patient with Small-Cell lung cancer. Case Rep Neurol Med. 2019;2019:5353202.
- Anderson CJ, Guidon AC, Khan FB, et al. Case report of lambert eaton myasthenic syndrome in a patient with small cell lung cancer on immune checkpoint inhibitor therapy. OBM Neurobiol. 2021;5(1):9. doi:10.21926/obm.neurobiol.2101086.
- Nakatani Y, Tanaka N, Enami T, et al. Lambert-Eaton myasthenic syndrome caused by nivolumab in a patient with squamous cell lung cancer. Case Rep Neurol. 2018;10(3):346–352.
- Weinmann SC, Pisetsky DS. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. Rheumatology (Oxford). 2019;58(Suppl 7):vii59–vii67.
- Kao JC, Liao B, Markovic SN, et al. Neurological complications associated with anti-Programmed death 1 (PD-1) antibodies. JAMA Neurol. 2017;74(10):1216–1222.
- Titulaer MJ, Lang B, Verschuuren JJGM. Lambert–eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098–1107.
- Gill AJ, Gandhy S, Lancaster E. Nivolumab-associated Lambert-Eaton myasthenic syndrome and cerebellar dysfunction in a patient with a neuroendocrine tumor. Muscle Nerve. 2021;63(3):E18–e21.
- Krishnan G, Wilson W. Immunotherapy related myasthenia gravis and lambert eaton syndrome case reports and review of literature. J Im-Muno Immunothe. 2020;3(007).
- Kunii E, Owaki S, Yamada K, et al. Lambert-Eaton myasthenic syndrome caused by atezolizumab in a patient with small-cell lung cancer. Intern Med. 2022.